Vis enkel innførsel

dc.contributor.authorStrand, Kristin Melheim
dc.contributor.authorOdland, Maria Lisa
dc.contributor.authorIversen, Ann-Charlotte
dc.contributor.authorNordbø, Svein Arne
dc.contributor.authorVik, Torstein
dc.contributor.authorAustgulen, Rigmor
dc.date.accessioned2017-10-09T07:12:05Z
dc.date.available2017-10-09T07:12:05Z
dc.date.created2012-10-03T08:13:06Z
dc.date.issued2012
dc.identifier.citationBJOG: an International Journal of Obstetrics and Gynaecology. 2012, 119 (11), 1316-1323.nb_NO
dc.identifier.issn1470-0328
dc.identifier.urihttp://hdl.handle.net/11250/2459070
dc.description.abstractObjective To assess the association between maternal cytomegalovirus (CMV) antibodies in mid-pregnancy and preeclampsia. Design Nested case–control study. Setting Pregnancies registered in the Norwegian Mother and Child Cohort Study (MoBa): a large population-based pregnancy cohort (1999–2006). Sample A cohort of 1500 women with pre-eclampsia and 1000 healthy pregnant women. Methods Plasma samples and pregnancy-related information were provided by the MoBa. Antibody status (CMV IgG and CMV IgM) and levels (CMV IgG) at 17–18 weeks of gestation were determined by enzyme-linked immunosorbent assay (ELISA). Main outcome measure A diagnosis of pre-eclampsia, as defined in the Medical Birth Registry of Norway. Results There was no evidence of an effect of CMV IgG seropositivity on the likelihood of developing pre-eclampsia, and CMV IgG antibody levels among women who were seropositive did not differ between groups. Adjusted for maternal age, parity and smoking, the odds ratio for pre-eclampsia in women seropositive for CMV IgG was 0.89 (95% CI 0.74–1.05; P = 0.17). The proportions of women who were seropositive for IgM did not differ between women with pre-eclampsia and women who were healthy (P = 0.98). Among nulliparous women, the proportion of women who were seropositive for CMV IgG was slightly lower among women with pre-eclampsia (53.5%) than among healthy women (59.8%) (P = 0.03). Subgroup analyses were performed for women with early or late onset pre-eclampsia, with preterm delivery and/or with neonates that were small for gestational age, but antibody status did not differ between pre-eclampsia subtypes and controls. Conclusions The presence of maternal antibodies to CMV was not associated with pre-eclampsia in our study. The results suggest that CMV infection is unlikely to be a major cause of preeclampsia.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.titleCytomegalovirus antibody status at 17 - 18 weeks of gestation and preeclampsia: a case-control study of pregnant women in Norwaynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber1316-1323nb_NO
dc.source.volume119nb_NO
dc.source.journalBJOG: an International Journal of Obstetrics and Gynaecologynb_NO
dc.source.issue11nb_NO
dc.identifier.doi10.1111/j.1471-0528.2012.03420.x
dc.identifier.cristin948308
dc.relation.projectNorges forskningsråd: 183234nb_NO
dc.description.localcodeThis is the peer reviewed version of the following article: Cytomegalovirus antibody status at 17 - 18 weeks of gestation and preeclampsia: a case-control study of pregnant women in Norway, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2012.03420.x/epdf. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.nb_NO
cristin.unitcode194,65,10,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for laboratoriemedisin, barne- og kvinnesykdommer
cristin.unitnameInstitutt for kreftforskning og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel